BMS Located in Hannover Germany, BMS manufactures and designs compression drivers of high and mid-high frequency range for pro audio applications along with cones, horns, coaxials, and a planar wave device. BMS precision drivers are used in professional speakers, cinema sound systems, stage monitors, recording studio monitors, home theater, high end audiophile speakers, and test systems. BMS designs and manufactures OEM compression drivers for many well known, highly respected pro audio speaker manufacturers throughout the world. Chances are you have already heard BMS drivers.
|Published (Last):||9 June 2010|
|PDF File Size:||17.95 Mb|
|ePub File Size:||5.13 Mb|
|Price:||Free* [*Free Regsitration Required]|
Bristol-Myers K. We believe that our collective resources will benefit the rheumatoid arthritis patients we serve. We are also very delighted to collaborate with Bristol-Myers Squibb on such an important product. PD-1 is expressed on the surface of activated T cells and is involved in the negative regulation of the immune response to tumor cells. In the U.
About ORENCIA in Japan Rheumatoid arthritis is an autoimmune disease characterized by inflammation of the joints as a result of the over-expression of pro-inflammatory cytokines. ORENCIA is a biologic therapy that works by inhibiting T-cell activation and suppressing the production of pro-inflammatory cytokines, which leads to the amelioration of the inflammation in joints of patients.
ORENCIA IV is available in more than 50 counties, and was launched in September in Japan where it is indicated for use in patients of rheumatoid arthritis for whom other therapies have failed. About Bristol-Myers Squibb Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
For more information about Bristol-Myers Squibb, visit www. Bristol-Myers Squibb Forward Looking Statement This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of , regarding the research, development and commercialization of pharmaceutical products.
Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations.
No forward-looking statement can be guaranteed. Among other risks, there can be no guarantee that the investigational compound described in this release will move from early stage development into full product development, that clinical trials of this compound will support a regulatory filing, or that this compound will receive regulatory approval or, if approved, become a commercially successful product. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
BMS 4538 1" HIGH FREQUENCY COMPRESSION DRIVER!!